BioNexus Gene Lab Corp. (NASDAQ:BGLC – Get Free Report) was the recipient of a significant decrease in short interest in the month of November. As of November 15th, there was short interest totalling 112,100 shares, a decrease of 20.2% from the October 31st total of 140,400 shares. Based on an average daily trading volume, of 367,700 shares, the days-to-cover ratio is currently 0.3 days. Currently, 1.0% of the company’s shares are short sold.
Institutional Inflows and Outflows
An institutional investor recently raised its position in BioNexus Gene Lab stock. Virtu Financial LLC raised its holdings in BioNexus Gene Lab Corp. (NASDAQ:BGLC – Free Report) by 79.9% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 47,037 shares of the company’s stock after acquiring an additional 20,888 shares during the period. Virtu Financial LLC owned about 0.27% of BioNexus Gene Lab worth $33,000 as of its most recent filing with the Securities and Exchange Commission. 18.85% of the stock is owned by institutional investors and hedge funds.
BioNexus Gene Lab Price Performance
Shares of BioNexus Gene Lab stock traded down $0.01 during trading on Friday, hitting $0.23. 49,080 shares of the company were exchanged, compared to its average volume of 585,751. The firm’s fifty day moving average price is $0.36 and its 200 day moving average price is $0.43. BioNexus Gene Lab has a 1-year low of $0.23 and a 1-year high of $3.39.
BioNexus Gene Lab Company Profile
BioNexus Gene Lab Corp., through its subsidiary, sells chemical raw material products in Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia. The company offers chemical raw material products, which include Polyester Resin SHCP 268, a thixotropic, quick-curing unsaturated polyester resin suitable as a general-purpose resin; Polyester Resin 9509, a general-purpose material used in production of marine boats and water slides; and Polyester Resin 2802 used as a component in the pultrusion process by certain manufacturers.
Featured Stories
- Five stocks we like better than BioNexus Gene Lab
- Using the MarketBeat Dividend Yield Calculator
- ServiceNow: Will the High-Flyer Finally Split in 2024?
- REIT Stocks – Best REIT Stocks to Add to Your Portfolio Today
- MarketBeat Week in Review – 11/25 – 11/29
- The How and Why of Investing in Gold Stocks
- These 3 Stocks Are Heavy Hitters in Alternative Asset Management
Receive News & Ratings for BioNexus Gene Lab Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioNexus Gene Lab and related companies with MarketBeat.com's FREE daily email newsletter.